Brief: Centessa Pharmaceuticals Initiates Global Phase 3 Action Study Of Lixivaptan In Autosomal Dominant Polycystic Kidney Disease

Centessa Pharmaceuticals

14/12/2021 12:59

Dec 14 (Reuters) - Centessa Pharmaceuticals PLC  260y.F :
    * CENTESSA PHARMACEUTICALS INITIATES GLOBAL PHASE 3 ACTION
STUDY
OF LIXIVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,
REPORTS INITIAL POSITIVE SAFETY DATA FROM ALERT STUDY, AND
ANNOUNCES NOTICE OF ALLOWANCE FOR KEY LIXIVAPTAN U.S. PATENT
APPLICATION
    * CENTESSA PHARMACEUTICALS - ALL 4 SUBJECTS IN ALERT STUDY
WHO
PREVIOUSLY DISCONTINUED JYNARQUE SUCCESSFULLY TITRATED TO
MAINTENANCE DOSE OF LIXIVAPTAN
    * CENTESSA PHARMACEUTICALS PLC - ISSUANCE OF NEW PATENT
WOULD
COVER USE OF LIXIVAPTAN IN ADPKD THROUGH AT LEAST 2038

Source text for Eikon:  ID:nGNXbg5TSl 
Further company coverage:  260y.F 

 ((Reuters.Briefs@thomsonreuters.com;))